Lerner Scott
Known title: CEOCIK: 0001870246
Lerner Scott's purchase track record
How the stock did after each of Lerner Scott's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 12, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-38.1%
3 months: -11.1%
Beat the S&P 500
0%
median -24.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2022 | SRXH | $25K | -12.7% | -58.4% | -1.3% |
| 11/24/2021 | SRXH | $2K | -11.1% | -35.7% | -15.4% |
| 11/12/2021 | SRXH | $6K | -4.1% | -38.1% | -14.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SRXH | ▲ Buy | Open Market | 12,500 | $25K | 5/16/2022 | View on chart |
| SRXH | ▲ Buy | Open Market | 17 | $42 | 5/16/2022 | View on chart |
| SRXH | ▲ Buy | Open Market | 512 | $2K | 11/24/2021 | View on chart |
| SRXH | ▲ Buy | Open Market | 1,530 | $6K | 11/12/2021 | View on chart |
| SRXH | ▲ Buy | Open Market | 20 | $78 | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
SRX Global liquidates two investments, adds Onconetix stake
SRX Global informed shareholders that it is liquidating two portfolio investments. The company also announced a new investment in Onconetix, a Nasdaq‑listed firm. These actions change the composition of SRX's holdings and could influence future cash flows. The stock is currently near its $1.57 support level.
SRX Global liquidates two investments, adds Onconetix stake. SRX Global informed shareholders that it is liquidating two portfolio investments. The company also announced a new investment in Onconetix, a Nasdaq‑listed firm. These actions change the composition of SRX's holdings and could influence future cash flows. The stock is currently near its $1.57 support level.